Previous close | 21.52 |
Open | 21.49 |
Bid | 21.51 x 800 |
Ask | 21.52 x 1300 |
Day's range | 21.43 - 21.57 |
52-week range | 10.84 - 24.08 |
Volume | |
Avg. volume | 2,228,291 |
Market cap | 5.545B |
Beta (5Y monthly) | 0.77 |
PE ratio (TTM) | 5.28 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.12 (5.20%) |
Ex-dividend date | 10 May 2024 |
1y target est | N/A |
JERSEY CITY, N.J., May 08, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the "Secured Notes") and $500 million of 7.875% senior unsecured notes due 2034 (the "Unsecured
JERSEY CITY, N.J., May 07, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the "secured notes") and $500 million of senior unsecured notes due 2034 (the "unsecu
JERSEY CITY, N.J., May 02, 2024--Organon Reports Results for the First Quarter Ended March 31, 2024